Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major ...
The way to bring down the political temperature is to invest in the one sector where the return may be larger than the ...
Rob Lott and Irene Papanicolas examine how Americans pay for health care through taxes, premiums, and out-of-pocket costs, ...
After a series of losses in constitutional challenges to the Medicare Drug Price Negotiation Program, the drug industry seems to be moving to challenging the program on statutory grounds.
Value-based care is conventionally classified as an alternative payment model. That classification mistakes the output for ...
Each of the several bipartisan bills being considered by Congress to promote biosimilar competition would have major implications for the pharmaceutical market.
In the early parallel years, hybrid rates ran 6.2 percentage points above digital-only rates in commercial plans and 9.3 ...
Six pending federal bills would regulate private equity in health care, from an outright ban to disclosure, licensing, and antitrust tools. Rather than a categorical ban, federal policy makers could ...
From regulatory efforts to streamline approvals to emerging AI-driven decision-making, this episode explores the forces ...
Our interest has not been to seek directly to narrow the compensation differentials that favor certain specialties over ...
The Evidence-Based Prevention Continuum provides a common language and understanding for how to categorize and scale such ...
In their 2026 legislative sessions, state policymakers considered and enacted a wide variety of bills to improve affordability and strengthen their health care markets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results